These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 22232487)

  • 21. Anti-macular degeneration agents.
    Rothen M; Jablon E; Monares G; Fontal MR; Alfaro DV
    Ophthalmol Clin North Am; 2005 Dec; 18(4):561-7. PubMed ID: 16314219
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dosing regimen and the frequency of macular hemorrhages in neovascular age-related macular degeneration treated with ranibizumab.
    Barbazetto I; Saroj N; Shapiro H; Wong P; Freund KB
    Retina; 2010 Oct; 30(9):1376-85. PubMed ID: 20683380
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Age-related macular degeneration; therapeutic options].
    La Heij EC; Liem AT; Hendrikse F
    Ned Tijdschr Geneeskd; 2001 Jul; 145(29):1390-7. PubMed ID: 11494688
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 results.
    Antoszyk AN; Tuomi L; Chung CY; Singh A;
    Am J Ophthalmol; 2008 May; 145(5):862-74. PubMed ID: 18321465
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Triple therapy for age-related macular degeneration.
    Augustin A
    Retina; 2009 Jun; 29(6 Suppl):S8-11. PubMed ID: 19553805
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ranibizumab versus verteporfin for neovascular age-related macular degeneration.
    Brown DM; Kaiser PK; Michels M; Soubrane G; Heier JS; Kim RY; Sy JP; Schneider S;
    N Engl J Med; 2006 Oct; 355(14):1432-44. PubMed ID: 17021319
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Stroke rates after introduction of vascular endothelial growth factor inhibitors for macular degeneration: a time series analysis.
    Campbell RJ; Bell CM; Paterson JM; Bronskill SE; Moineddin R; Whitehead M; Gill SS
    Ophthalmology; 2012 Aug; 119(8):1604-8. PubMed ID: 22717458
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Innovative treatments for exudative age-related macular degeneration.
    Kim RW; Heier JS
    Int Ophthalmol Clin; 2004; 44(4):41-50. PubMed ID: 15577563
    [No Abstract]   [Full Text] [Related]  

  • 29. Approaches toward combining photodynamic therapy with pharmaceuticals that alter vascular microenvironment.
    Busch T
    Retina; 2009 Jun; 29(6 Suppl):S36-8. PubMed ID: 19553798
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combined Pegaptanib sodium (Macugen) and photodynamic therapy in predominantly classic juxtafoveal choroidal neovascularisation in age related macular degeneration.
    Calvo-González C; Reche-Frutos J; Donate-López J; García-Feijoó J; Leila M; Fernández-Pérez C; Garcia-Sánchez J
    Br J Ophthalmol; 2008 Jan; 92(1):74-5. PubMed ID: 18156376
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Verteporfin photodynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degeneration.
    Kaiser PK; ; Boyer DS; Garcia R; Hao Y; Hughes MS; Jabbour NM; Kaiser PK; Mieler W; Slakter JS; Samuel M; Tolentino MJ; Roth D; Sheidow T; Strong HA
    Ophthalmology; 2009 Apr; 116(4):747-55, 755.e1. PubMed ID: 19243834
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Position of the Retinological Society, the German Ophthalmological Society and the Professional Association of Ophthalmologists in Germany on the current therapeutic possibilities for neovascular age-related macular degeneration].
    Klin Monbl Augenheilkd; 2007 Jul; 224(7):559-66. PubMed ID: 17657689
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ranibizumab monotherapy for sub-foveal haemorrhage secondary to choroidal neovascularisation in age-related macular degeneration.
    McKibbin M; Papastefanou V; Matthews B; Cook H; Downey L
    Eye (Lond); 2010 Jun; 24(6):994-8. PubMed ID: 19911016
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Angiogenesis inhibitors: an upcoming therapy for cancer and wet age-related macular degeneration.
    Sweeney K
    Drug Discov Today; 2005 Oct; 10(20):1346-8. PubMed ID: 16253870
    [No Abstract]   [Full Text] [Related]  

  • 35. Antiangiogenic approaches to age-related macular degeneration today.
    Bressler NM
    Ophthalmology; 2009 Oct; 116(10 Suppl):S15-23. PubMed ID: 19800535
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ranibizumab for the treatment of neovascular age-related macular degeneration: a review.
    Kourlas H; Abrams P
    Clin Ther; 2007 Sep; 29(9):1850-61. PubMed ID: 18035187
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration.
    Goff MJ; Johnson RN; McDonald HR; Ai E; Jumper JM; Fu A
    Retina; 2007; 27(4):432-8. PubMed ID: 17420694
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Triple therapy for choroidal neovascularization due to age-related macular degeneration: verteporfin PDT, bevacizumab, and dexamethasone.
    Augustin AJ; Puls S; Offermann I
    Retina; 2007 Feb; 27(2):133-40. PubMed ID: 17290193
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month results of the DENALI study.
    Kaiser PK; Boyer DS; Cruess AF; Slakter JS; Pilz S; Weisberger A;
    Ophthalmology; 2012 May; 119(5):1001-10. PubMed ID: 22444829
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month MONT BLANC study results.
    Larsen M; Schmidt-Erfurth U; Lanzetta P; Wolf S; Simader C; Tokaji E; Pilz S; Weisberger A;
    Ophthalmology; 2012 May; 119(5):992-1000. PubMed ID: 22424834
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.